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Bascil S1, Serinsoz H2, Tutuncu NB2
Baskent University Faculty of Dentistry, Department of Periodontology, Adana, Turkey. 
neslibascil@yahoo.com
Abstract: Background: Acromegaly is a complex syndrome which infl uences the connective tissue and bone 
metabolism. Although the effects of excess growth hormone on bone tissue are well known, its effect on 
periodontal tissue is an enigma. 
Methods: A total of 23 acromegalic patients (mean age 48.13 ± 9.4 years) were included randomly in to this 
cross-sectional study. The control group consisted of 60 healthy (mean age 50.3 ± 8.5) individuals. All partici-
pants were examined by the same periodontist to evaluate periodontal disease status.
Results: We studied a group of 23 acromegalic patients (11 females, 12 males) with estimated duration of dis-
ease from minimum of one year to 10 years (mean 4.52 ± 2.9 years). The frequency of advanced chronic peri-
odontitis in acromegalics was signifi cantly lower than in the healthy group (p = 0.002). Advanced periodontitis 
was 10 times more frequent in healthy population than in the acromegalics. 
Conclusions: Advanced chronic periodontitis is 10 times less frequent in acromegalics than in healthy popu-
lation. Acromegaly is a disease which seems to be protective for periodontal tissue (Tab. 4, Ref. 30). Text in 
PDF www.elis.sk.
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Acromegaly is a rare disease characterised by uncontrolled 
secretion of growth hormone (GH) from the hypophysis. It is usu-
ally asymptomatic unless it reaches 10 mm in size. In the advanced 
stage, it has typical oral features of prognathism, macroglossia, 
increased interdental spaces and dental mobility as well as the 
systemic features of enlarged hands and feet, bulging of the fron-
tal bone, cardiovascular diseases, osteoarthritis and sleep apnea 
(1). Although its typical characteristics are well known, little is 
known about the periodontal status of these patients in different 
stages of the disease. 
Acromegalic patients have increased GH, insulin like growth 
factor-1 (IGF-1), insulin like growth factor binding protein-3 and 
calcitriol levels. These directly affect the bone cells and connective 
tissue. Likewise, coexistence of hypogonadism, thyroid hormone 
imbalance and glucose intolerance may all have an impact on the 
periodontal tissue and bone. In this complicated network of in-
fl uencing factors it is hard to defi ne a specifi c periodontal disease 
for acromegalic patients (2–9). 
In the periodontal tissue direct and indirect effects of GH/IGF-1 
system is not well known but it is a hot topic in the fi eld of ortho-
dontics and implantation. Osteoblasts are the leading cells in bone 
which regulate bone dynamics by timing bone remodelling under 
different infl uences. Likewise human periodontal ligament (PDL) 
cells behave like osteoblasts and are the master cells in periodon-
tal tissue regulating connective tissue resorption or synthesis in 
different clinical situations. PDL cells are different from gingival 
fi broblasts in that they proliferate at a higher rate and show higher 
levels of cAMP production and greater ALP-ase activity (10–11). 
Kanzaki H and friends discovered that PDL cells not only support 
osteoclasts genesis through cell-to-cell contact, but also inhibit 
the formation of tartrate-resistant acid phosphatase-positive mul-
tinucleated cells by producing soluble factor(s) (12). Furthermore, 
PDL cells express both receptor activator of nuclear factor kappa B 
ligand and osteoprotegerin messenger RNA, like osteoblasts. They 
were shown to modulate osteoclastogenesis in different situations 
like mechanical stress and infl ammation (13–14).
In light of these studies we hypothesized an anabolic state of 
periodontal matrix as a consequence of excess GH/IGF-1 in acro-
megalics. In our study we aimed to explore the periodontal tissue 
involvement in the clinical presentation of acromegaly and com-
pare it with the healthy age and sex matched volunteers.
Materials and methods
A total of 23 acromegalic patients (mean age 48.13 ± 9.4 years) 
were included randomly into this cross-sectional study. Patients 
with the diagnosis of acromegaly were selected randomly from 
the outpatient clinic of the Endocrinology Department at Baskent 
University, Faculty of Medicine, during routine periodic control 
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visits. The following variables were specifi cally recorded: age, 
body mass index, duration of the disease, history of pituitary sur-
gery and radiotherapy, activity of the disease, IGF-1 and IGFBP-3 
levels, treatment with a sandostatin analogue, length of remission, 
evaluation of anterior hypophysis hormonal reserve, renal and liver 
function tests. Exclusion criteria involved the other conditions 
known to infl uence the periodontal tissue and bone by causing 
osteopenia. These were chronic renal failure, hyperthyroidism or 
hyperparathyroidism and active smoking. The control group con-
sisted of 60 healthy individuals (mean age 50.3 ± 8.5) who were 
randomly selected from relatives or friends of the hospital staff with 
similar age and social economic status. Patients were systemically 
healthy, had not received anti-infl ammatory agents, antibiotics or 
immunosuppressants in the past 6 months, and had never smoked. 
All acromegalic patients and individuals in the control group 
were examined by the same experienced periodontist. Periodontal 
pocket depth (presence of an abnormal gingival sulcus near the 
point at which the gums contact tooth) was evaluated using peri-
odontal probe at six different points of each tooth. Individuals with 
probing pocket depth (PPD) between 4–6 mm and clinical attach-
ment level (CAL = amount of space between attached periodontal 
tissues and a fi xed point, usually the cementoenamel junction) up 
to 4 mm as having chronic periodontitis with slight to moderate 
loss of periodontal support (15). Those with PPD ≥ 6 mm and CAL 
greater than 4 mm were diagnosed as having chronic periodontitis 
with advanced loss of periodontal support (16). 
Bleeding on probing which was considered an objective in-
fl ammatory parameter in periodontitis establishment, was mea-
sured using gingival bleeding index (GBI) (17). Gingival bleed-
ing index ≤ 0.1 was considered as low risk for the development 
of periodontitis. Tooth mobility levels were evaluated and classi-
fi ed (18) as degrees 1, 2, and 3. Radiographic examinations, tooth 
loss, diastemas (space or gap between two teeth) and malocclusion 
were also assessed.
Individuals from both groups were asked to fi ll a question-
naire about oral hygiene and frequency of dentist visits till today.
Patientslinical data were evaluated and assessed by the same 
experienced endocrinologist.
The diagnosis of acromegaly was established clinically and 
confi rmed by high serum GH concentrations that were not sup-
pressed after oral glucose tolerance test (75 g), elevated IGF-1 
levels for age and sex and demonstration of the pituitary tumor 
by computed tomographic scan or magnetic resonance imaging. 
The estimated duration of the disease was determined according to 
the clinical history and review of the past photographs of the pa-
tients. The disease activity was assessed by GH suppression during 
OGTT. Hormonal status of anterior hypophysis was analysed by 
both basal serum pituitary hormone levels (ACTH, PRL, FSH, LH, 
TSH) with their end organ hormones and dynamic tests (19, 20). 
All ethical aspects were rigidly observed, the study was con-
ducted only after its approval by the local ethics committee. All 
patients gave informed consent to participate in this study in ac-
cordance with Helsinki declaration.
Serum levels of GH, IGF-1 and IGFBP-3 were determined by 
commercially available kits: chemiluminescent enzyme immu-
nometric assay for GH (Immulite Growth Hormone, Diagnostic 
Products Corp., CA, USA); immunoradiometric assay (Diagnos-
tic Systems Laboratories, DSL-6600 ACTIVE) for IGFBP-3; 
highly sensitive and specifi c immunoradiometric assay which 
uses modifi ed form of the standard acid-ethanol extraction pro-
cedure (Diagnostic Systems Laboratories, DSL-5600 ACTIVE) 
for plasma IGF-1. 
Descriptive statistical values for the study group are expressed 
as mean ± standard deviation for continuous variables and as 
proportions for ordinal (categorical) variables, such as gender, 
smoking, radiotherapy, operations or presence of hypogonad-
ism, periodontitis and malocclusion. Differences within patient 
clinical characteristics and comparisons with the healthy control 
group were assessed for statistical signifi cance using the Student's 
t test and the Chi-square, where appropriate. Correlations between 
acromegaly disease duration, disease activity status and oral pa-
thologies in the acromegalic patients were tested using Pearson 
Acromegaly Patients Healthy Control Group p
n 23 60 -
Age (years) 48.13±9.4 50.32±8.5 NS
Sex (F/M) 11/12 34/26 NS
Duration of acromegaly (years) 4.52 ± 2.9 - NS
Acromegaly- cured 1/23 - -
Acromegaly-inactive with medication 10/23 - -
Acromegaly-active 12/23 - -
Chronic Periodontitis 12/23 (52.2%) 40/60 (66.7%) NS
Slight-moderate chronic periodontitis 11/23 (47.8%) 14/60 (23.3%) NS
Advanced chronic periodontitis 1/23 (4.3%) 26/60 (43.3%) 0.002
No periodontal pathology 11/23 (47.8%) 20/60 (33.3%) NS
Macroglossia 9/23 (39.1%) 0 0.0001
Hypogonadism 6/23 (26.1%) 0 0.0001
Past-smoker 2/23 (8.7%) 0 0.0001
Disorder of Glucose Metabolism 13/23 0 0.0001
NS = nonsignifi cant
Tab. 1. Clinical characteristics of the acromegalics and control group.
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correlation. Statistical signifi cance was considered when a two-
sided p value was 0.05 or below. The statistical software PASW 
was used for statistical analysis.
Results
We studied a group of 23 patients (11 females, 12 males) with 
estimated duration of the disease from minimum of one year to 
10 years (mean 4.52 ± 2.9 years). There were two past smokers 
in the acromegaly patient group and none in the healthy control 
group. These 2 patients smoked up to 5 and 10 cigars per day for 
4 years and 7 years, respectively. They both quit smoking more 
than 5 years ago. There were 6 patients diagnosed with hypogo-
nadism after surgery and they received hormonal replacement. 
Patients with hypogonadism did not have lumbar and femoral os-
teoporosis. Among the acromegalics, 13 had glucose intolerance 
among which 6 received oral drugs and others were treated with 
diabetic diet. Clinical characteristics of acromegalic patients and 
the control group are shown in Table 1.
Twelve patients had been submitted to pituitary surgery and 3 
patients had radiotherapy. Somatostatin analogue, either Octreotide 
or Lanreotide was given to all 23 patients to control GH secretion 
at the hypophyseal level. Disease cure was defi ned when all these 
criteria were met: random GH level less than 2.5 mg/L and plasma 
IGF-1 levels normal for age and GH suppressed during OGTT and 
the patient is not taking any sandostatin analogue. There was only 
one patient in whom the disease was cured. Disease was defi ned as 
inactive when random GH level was less than 2.5 μg/L and plasma 
IGF-1 levels were normal for age under a sandostatin analogue. 
There were 10 patients with inactive disease. Those having high 
GH and or IGF-1 levels had active, uncontrolled disease (n = 12). 
There were 6 patients with hypogonadism and 13 patients with 
a disorder of glucose metabolism (Tab. 2). The duration of acro-
megaly was found to be negatively correlated with hypophyseal 
disease activity (p = 0.01). More patients had controlled disease 
as the duration from the time of diagnosis increased. 
Our study revealed signifi cantly lower frequency of advanced 
chronic periodontitis in the acromegalics compared to the healthy 
group (p = 0.002). About 43.3 % (26/60) of the healthy group and 
4.3 % (1/23) of the acromegalics had advanced chronic periodon-
titis. That is advanced periodontitis was 10 times more frequent in 
healthy population than in the acromegalics. Among the acrome-
galics about 47.8 % of them had healthy periodontal tissue while 
this rate was about 33.3 % in the healthy population. Clinical peri-
odontal disease status of the acromegalics and healthy volunteers 
is shown in Table 3.
Among the acromegalics those with active disease (high plas-
ma GH and/or IGF-1 levels) showed signifi cantly increased fre-
quency of chronic periodontitis (slight-to-moderate and advanced) 
compared to those with inactive or cured disease (normal plasma 
GH and/or IGF-1 levels) (p = 0.011) (Tab. 4). Inactive disease 
duration (length of remission) was found to be negatively cor-
related with chronic periodontitis of any degree (p = 0.030). As 
the time period of normal/near normal plasma GH/IGF-1 level 
increased (control of acromegaly or length of remission) patients 
encountered with chronic periodontitis decreased. Also the de-
gree of chronic periodontitis (slight-to-moderate or advanced) 
was found to be positively correlated with activity of acromegaly 
(p = 0.043). Frequency of smokers, glucose intolerance, macro-
glossia and hypogonadism were similar in acromegalics with and 
without active disease.
Discussion
Periodontal disease is an infection driven chronic infl ammatory 
disease characterized by resorption of tooth-supporting alveolar 
bone. The etiology of this disease is complex and multifactorial 
involving both genetic and environmental factors. Although up to 
50 % of periodontitis susceptibility is credited to hereditary factors 
in oral tolerance and regulation of mucosal immunity based on 
n (%)
Total acromegaly patients 23
Acromegaly- cured 1 (4.3)
Acromegaly-inactive with medication 10 (43)
Acromegaly-active 12 (52.2)
Macroglossia 9 (39.1)
Hypogonadism 6 (26.1)
Past-smoker 2 (8.7)
Disorder of Glucose Metabolism 13 (56.5)
Pituitary surgey 12 (52.2)
Radiotherapy 3 (13.0)
Somatostatin analogs 23  (100)
Tab. 2.  Clinical characteristics of acromegalic patients.
Acromegalics with 
periodontitis
Acromegalics without 
periodontitis
Healthy controls with 
periodontitis
Healthy controls without 
periodontitis
GBI 1.86  ± 0.34 0.75  ± 0.56 1.92 ± 0.72 0.91 ± 0.40
PPD 4.60 ± 1.00 2.23 ± 0.87 5.12 ± 0.54 1.93 ± 0.65
CAL 3.88  ± 1.30 0.39 ± 1.29 4.01  ±1.24 0.62 ± 0.28
PI 1.90  ± 0.46 1.28 ± 0.44 2.1 ± 0.62 1.14 ± 0.47
GBI = gingival bleeding index; PPD = periodontal probing depth; CAL = clinical attachment loss; PI = plaque index
Tab. 3. clinical periodontal status of the acromegalic patients  and the healthy controls.
n Chronic periodontitis 
cases (n)
Acromegalic patients/Disease active 12 10
Acromegalic patients/Disease cured or inactive 11 3
p NS 0.011
NS = nonsignifi cant
Tab. 4. Chronic periodontitis cases in acromegalics.
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family studies, twin studies, and population studies, environmental 
factors are very important in most populations and disease states.
In the present study, evaluation of periodontal status of 23 acro-
megalic patients revealed that advanced chronic periodontitis is en-
countered less frequently in acromegalics compared to healthy pop-
ulation. Interestingly, in our study population healthy volunteers 
revealed chronic periodontitis more often than the acromegalics. 
Our fi ndings demonstrate that two of three (66.7 %) otherwise 
healthy Turkish people have some degree of chronic periodontitis. 
Similar to our fi ndings, prevalence of chronic periodontitis was 
found to be 40–70 % in other studies of otherwise healthy Turkish 
population. Due to this high prevalence of periodontitis, Saydam 
G. and friends underlined the importance of preventive periodon-
tal therapy and community-based prophylaxis methods for future 
nationwide dental health service planning in Turkey (21–24).
Although GH excess has complex consequences on bone and 
connective tissue metabolism there is yet very few data about 
periodontal pathologies in these patients (25–27). As long as our 
English literature search is concerned, we could fi nd only one 
study evaluating the periodontal status in acromegalics. In accor-
dance with our fi ndings, in the study of Lima et al, they found no 
periodontitis in 16 acromegalics despite the presence of diabetes 
mellitus (28). There are many hormones effecting periodontal tis-
sue including the sex hormones, parathyroid and thyroid hormones 
and GH. Osteoblasts have GH receptors and after stimulation by 
this hormone they increase matrix formation. It also has indirect 
actions via IGF-1 which via autocrine and paracrine effects is 
anabolic for bone (21). In recent years, it is postulated that IGF-1 
has impact on periodontal ligament fi broblasts and has protective 
effect for periodontitis in acromegalic patients. In this regard GH 
has been used to improve dental peri-implant bone tissue. Likewise, 
several reports have documented that in adults with isolated GH 
defi ciency, which is an opposite clinical situation with acromegaly, 
chance of having periodontal attachment loss (PAL) is increased 
compared to healthy individuals (28, 30). 
In search for the integrating situations affecting the periodontal 
tissue in acromegalics we analysed the hormonal status, smoking 
habits and glucose metabolism of the patients in our study. Inter-
estingly, we found no association with the gonadal and glycemia 
status nor the treatment strategies including surgery, radiotherapy 
and sandostatin analogue therapy with the periodontal well-being. 
Having dysglycemia (n = 13), history of hypogonadism (n = 6) and 
smoking (n = 2) in acromegalic group did not end up with more 
severe oral periodontal disease status compared with the controls.
It was surprising to fi nd out that although acromegaly is a dis-
ease which seems to be protective for periodontal tissue, disease 
activity had negative impact. We found that chronic periodontitis 
was more often encountered in acromegalic patients with active 
disease, that is those having high GH/IGF-1 levels at that time 
point. In parallel with this fi nding, we also found that among the 
acromegalics with longer duration of disease control (with low 
GH/IGF-1 levels), fewer periodontitis cases and periodontitis with 
lesser degrees were diagnosed. This may be due to a statistical 
bias because of the small number of acromegalic patients in our 
study or inadequate evaluation of confounding factors affecting 
the periodontal tissue. This may also be a consequence of longer 
cumulative GH/IGF-1 excess in those with longer duration of ac-
romegaly. In our study, those acromegalics with longer remission 
period with controlled hormone levels also have longer acromegaly 
duration. It was interesting to note that among the acromegalics 
we studied, there was only one case with advanced chronic peri-
odontitis in whom acromegaly was diagnosed very recently, and 
thus the disease was not controlled yet. In this index case cumu-
lative amount of excess GH/IGF-1 is expected to be small as the 
disease was diagnosed recently. 
In our opinion, the cumulative amount of excess GH/IGF-1 
exposure may be the main protective factor for periodontal tissue. 
Detailed analysis in a prospectively designed clinical trial with 
periodic measurements of plasma GH/IGF-1 levels from the time 
of diagnosis of acromegaly would give more clear data about the 
role of GH/IGF-1 system on periodontal tissue. 
Importantly, possible major bias is the fact that patients with 
acromegaly may be more likely to visit a dentist due to their teeth 
problems therefore have better dental care. In fact, for our acro-
megaly patients, this was not the case according to the question-
naire answered about oral hygiene and past dentist visits. 
We are aware of the possible selection bias both in acrome-
galics and control subjects which may not truly refl ect what is hap-
pening in real life and does not allow to conclude that acromegaly 
is protective for periodontal disease. Keeping in mind this and that 
acromegaly is a very rare disease with a prevalence of 50–70 cases 
per million persons, it is usually hard to evaluate large numbers of 
cases in a single centre. We conclude that acromegaly is a disease 
with possible protective effects on the periodontal tissue. This very 
early conclusion is drawn from our preliminary study and from 
that of Lima et al. Among the very few studies evaluating oral 
pathologies and especially the periodontal tissue in acromegalics, 
our study forms the basis for future studies with larger groups of 
patients aimed to fi nd out the chronic periodontitis frequency and 
factors infl uencing periodontal tissue in these patients. 
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